Navigation Links
Penn team uses self-assembly to make molecule-sized particles with patches of charge
Date:10/20/2009

PHILADELPHIA - Physicists, chemists and engineers at the University of Pennsylvania have demonstrated a novel method for the controlled formation of patchy particles, using charged, self-assembling molecules that may one day serve as drug-delivery vehicles to combat disease and perhaps be used in small batteries that store and release charge.

Researchers demonstrated that the positive electrical charges of calcium ions just like the calcium in teeth and bone can form bridges between negatively charged polymers that would normally repel each other. The polymers, similar to the lipids that make the membranes surrounding living cells, have both a water-loving part linked to a water-repelling part. On the surfaces of these cell-sized polymer sacks, the calcium ions create calcium-rich islands or patches on top of negatively-charged polymer. Copper ions also work, and the patches can be made to coalesce and cover half of the particle. This polarized structure is the basic arrangement needed to set up, for example, the two electrodes of a microscopic battery. They could also one day be functionalized into docking sites to enhance targeted delivery of drug-laden particles to cells.

While the concept seems simple, that opposite charges attract, the creation and control of patches on one small particle has been a challenge. Scientists like Dennis E. Discher, principal investigator of the study and a professor of chemical and biomolecular engineering at Penn, are designing materials at the nanoscale because future technologies will increasingly rely on structures with distinct and controlled surfaces. Physicians, for example, will improve medical therapies by wrapping drugs within the bioengineered polymer sacks, or by creating tiny biomedical sensors. Green energy production and storage will also require structures with scales no longer measured by inches, but by micrometers and nanometers.

The collaboration involved faculty from Penn's
'/>"/>

Contact: Jordan Reese
jreese@upenn.edu
215-573-6604
University of Pennsylvania
Source:Eurekalert

Page: 1 2

Related biology news :

1. Clemson bioengineer uses nanoparticles to target drugs
2. Do dust particles curb climate change?
3. Therapeutic nanoparticles give new meaning to sugar-coating medicine
4. Carbon nanoparticles toxic to adult fruit flies but benign to young
5. New insights into health and environmental effects of carbon nanoparticles
6. Facile synthesis of nanoparticles with multiple functions advanced in Singapore
7. University of Leicester researchers discover new fluorescent silicon nanoparticles
8. New nanoparticles could revolutionize therapeutic drug discovery
9. Shape matters in the case of cobalt nanoparticles
10. UCSD researchers make first direct observations of biological particles in high-altitude ice clouds
11. To fight drug addiction, UB researchers target the brain with nanoparticles
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2015)... 23, 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... growing mobile commerce market, announces its biometric payment technology, the ... CNBC television starting March 30 th . ... New York markets. ... excited about our new ad campaign following the recent initial ...
(Date:3/20/2015)... 19, 2015 Research and Markets ( http://www.researchandmarkets.com/research/rswjb4/hand_geometry ... - Global Strategic Business Report" report to their offering. ... Geometry in US$ Thousands. The report provides separate comprehensive analytics ... Japan , Europe , ... Rest of World. Annual estimates and forecasts are ...
(Date:3/20/2015)... Markets ( http://www.researchandmarkets.com/research/vkzvcs/iris_biometrics ) has announced the addition ... report to their offering. This report analyzes ... report provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , ... . Annual estimates and forecasts are provided for ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 2Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 4Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 2Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 4Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 5
... -- In the largest undertaking of its kind, scientists ... a five-year National Institutes of Health (NIH)-funded study to ... the exact causes of hemoglobin toxicity. Hemoglobin in ... can become deadly when cells break open and spill ...
... no scientific evidence that low-level electromagnetic field exposure ... adverse health effects, according to a report presented ... Committee provides advice to authorities about risk management ... assessed the health hazards from low-level electromagnetic fields ...
... Research Institute and Sea Lane Biotechnologies have solved the co-crystal ... in a unique way. The antibody recognizes the crucial structure ... though previously this structure had been thought too small for ... hit this precise spot by using just a small part ...
Cached Biology News:Rice to take part in $10.8 million study of hemoglobin toxicity 2Rice to take part in $10.8 million study of hemoglobin toxicity 3Mobile phones and wireless networks: No evidence of health risk found 2Mobile phones and wireless networks: No evidence of health risk found 3Mobile phones and wireless networks: No evidence of health risk found 4Flu antibody’s 'one-handed grab' may boost effort toward universal vaccine, new therapies 2Flu antibody’s 'one-handed grab' may boost effort toward universal vaccine, new therapies 3
(Date:3/25/2015)... CAMBRIDGE, Mass. and REYKJAVIK, Iceland ... provides comprehensive capabilities for using the genome to create better ... publication of the largest studies of whole-genome data yet undertaken. ... Nature Genetics – are built around ... authored by a team of deCODE scientists led by ...
(Date:3/25/2015)... (PRWEB) March 25, 2015 Data ... Novel Mechanism of Action in Neuromuscular Diseases ... – Cytokinetics, Incorporated (Nasdaq: CYTK) announced the publication ... muscle troponin activator tirasemtiv in the journal Neurotherapeutics. ... IIa “Evidence of Effect” or hypothesis-generating clinical trial ...
(Date:3/25/2015)... the HAGUE, Netherlands , March 25, ... LES Stimulation therapy for chronic gastro-esophageal reflux disease (GERD) ... [ Surgery . 2015; 157(3):556-567 ], establishing ... therapy. The study included 25 patients ... years and taking prescribed daily proton pump inhibitor (PPI) ...
(Date:3/25/2015)... March 25, 2015  18 piglets born recently ... research by scientists in the College of Agriculture and ... a breakthrough in the field of genetic engineering. ... of Animal & Avian Sciences (ANSC) and Ki-Eun ... successfully produced genome-edited pigs using a recently developed, ...
Breaking Biology Technology:Landmark deCODE Studies Demonstrate the Power of Truly Big Genomics for Improving Medicine Worldwide 2Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 2Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 3Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 4Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 5Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 6EndoStim LES Stimulation therapy demonstrates long term safety and efficacy results in treating reflux patients 2EndoStim LES Stimulation therapy demonstrates long term safety and efficacy results in treating reflux patients 3University of Maryland Researchers Successfully Produce Genome-edited Pigs Using Revolutionary Technology 2
... FRANCISCO, CA -- September 6, 2007 -- Researchers at ... College of Medicine have discovered a mechanism by which ... disease. AB, which is known to accumulate in the ... of research into the causes and treatment of the ...
... ThermoGenesis,Corp. (Nasdaq: KOOL ), a leading supplier ... administer therapeutic doses of,adult stem cells for treatment of ... for the fourth quarter and full year ended,June 30, ... Call and Webcast Management will host a conference ...
... in Sales by 2016, According to a ... New Report from Decision Resources, WALTHAM, Mass., ... and advisory firms for pharmaceutical and,healthcare issues, finds that Amgen, the ... billion in 2006, and Genentech,the second leading biologics manufacturer with biologic ...
Cached Biology Technology:Gladstone scientists uncover potential mechanism of memory loss in Alzheimer's disease 2ThermoGenesis Corp. to Announce Fourth Quarter and Year End Results for Fiscal Year 2007 on September 12, 2007 2ThermoGenesis Corp. to Announce Fourth Quarter and Year End Results for Fiscal Year 2007 on September 12, 2007 3Amgen and Genentech Brace Themselves for Heavy Pressure From Biogenerics Manufacturers 2
Rabbit polyclonal to ZFP200 ( Abpromise for all tested applications). Antigen: Synthetic peptide: CGKSFNHKTNLNKHER (Human) Entrez Gene ID: 7752 Swiss Protein ID: P98182...
Human Ig Lambda-chain, clone ICO-16, Monoclonal Antibody...
Rabbit polyclonal to Warfarin ( Abpromise for all tested applications). Antigen: Chemical / Small Molecule conjugated to KLH...
WNV Core Antibody...
Biology Products: